Lifeloc Technologies, INC 8-K filings

Lifeloc Technologies announced second quarter 2026 results, showing a 10% increase in net revenue to $2.445 million and improved gross margins, though the company reported a net loss of $134,000.

Lifeloc Technologies announced the resignation of its auditor due to a business sale and the approval of amended articles of incorporation at its annual meeting.

Lifeloc Technologies announced first quarter 2026 results, showing a slight revenue increase and a reduced net loss, alongside a significant development milestone for its SpinDetect drug analyzer.

Lifeloc Technologies has entered into a $500,000 promissory note with its CFO to fund the development of its SpinDetect product.

Lifeloc Technologies announced a 6% increase in 2025 revenue to $9.027 million, alongside a higher net loss of $2.470 million primarily due to a non-cash deferred tax valuation allowance.

Lifeloc Technologies, Inc. announced its third quarter 2025 financial results, reporting increased revenue but a wider net loss driven by R&D investments in its SpinDetect drug analyzer.

Lifeloc Technologies, Inc. has entered into a definitive merger agreement to acquire Electronic Systems Technology, Inc., making ELST a wholly-owned subsidiary.

Lifeloc Technologies will present an update on its SpinDetect drug analyzer and current operations at the Emerging Growth Conference on September 25, 2025.

Lifeloc Technologies, Inc. has amended a significant license agreement with National Technology & Engineering Solutions of Sandia, LLC, modifying key operational and governance provisions.

Lifeloc Technologies reported a 7% decline in second-quarter 2025 net revenue and an increased net loss, while continuing significant investment in its SpinDx drug testing platform.

Lifeloc Technologies, Inc. announced the successful re-election of its five-member Board of Directors and the ratification of Assure CPA as its independent registered public accountants for fiscal year 2025 at its Annual Meeting of Shareholders held on June 4, 2025.

Lifeloc Technologies announces a 6% increase in revenue for Q1 2025, driven by L-series devices, while continuing to invest heavily in SpinDx development.

Lifeloc Technologies reports a decrease in revenue and a net loss for 2024, while investing heavily in the development of its SpinDx drug detection technology.

Lifeloc Technologies has secured $750,000 in subordinated debt financing from Diamond Bridge Capital, along with a warrant to purchase shares, to support growth and the commercialization of its SpinDx technology.

Lifeloc Technologies reported a decrease in revenue and a net loss for the third quarter of 2024, while making progress on its SpinDx drug testing technology.

Lifeloc Technologies announced a net loss for the second quarter of 2024, despite a 5% increase in revenue, due to significant investments in research and development, particularly for their SpinDx technology.

Lifeloc Technologies has announced a private placement raising $798,000, the appointment of Adam Kashenberg to its board, and a $750,000 line of credit.

Lifeloc Technologies held its annual shareholder meeting on June 19, 2024, where directors were elected and the company's auditors were ratified.

Lifeloc Technologies has dismissed GreenGrowth CPAs and appointed Assure CPA as its new independent auditor, effective May 22, 2024.

Lifeloc Technologies announced its first quarter 2024 results, showing a slight revenue decrease and a larger net loss compared to the same period last year, primarily due to increased research and development investments.

Lifeloc Technologies reports a profitable 2023 with $206 thousand in net income, a significant turnaround from a net loss in 2022, driven by a 10% revenue increase and improved gross margins.